Daniel E. Abbott, MD, FACS

Professor

  • Surgical Director, UW Health Liver and Pancreas Center
  • Division of Surgical Oncology

abbott@surgery.wisc.edu
(608) 262-2025

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Box 7375, Clinical Science Center
Madison, WI 53792

Education

  • MD, University of Washington School of Medicine, Seattle, Washington
  • General Surgery Residency, Northwestern University/Feinberg School of Medicine, Chicago, Illinois
  • Research Fellowship, Children's Memorial Research Center/Northwestern University, Division of Cancer Biology and Epigenomics, Chicago, Illinois
  • Surgical Oncology Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Clinical Specialties

Dr. Abbott is certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. Trained specifically in cancer surgery at The University of Texas MD Anderson Cancer Center, his clinical focus is on gastrointestinal malignancies, as well as melanoma and sarcoma. He performs both traditional and laparoscopic resections for cancers of the liver, pancreas, and stomach. As Director of Cytoreductive and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery, he is particularly interested in patients with peritoneal spread of appendiceal, colorectal and ovarian cancers. Dr. Abbott is active in a number of national organizations, including the Society of Surgical Oncology, the American Hepatopancreaticobiliary Association, the Association for Academic Surgery, and the Society of University Surgeons.

Research Interests

Dr. Abbott, a health services researcher, focuses on cost-effectiveness, systems efficiency, and socioeconomic disparity in cancer care. He is particularly interested in identifying opportunities to maintain or enhance cancer care using technology in a patient-centered manner and thereby helping patients access expert cancer care in more personalized settings.

Recent Publications

  • The overlooked factor: The impact of disability on postoperative complications after emergency general surgery procedures surgery.
    Sigler G, Abbott DE
    Surgery 2024 Apr 12;
    [PubMed ID: 38614910]

  • Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.
    Fackche NT, Schmocker RK, Nudotor R, Kubi B, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Wilson GC, Lambert LA, Pokrzywa C, Abbott DE, Lee B, Staley CA, Zaidi MY, Johnston FM, Greer JB
    Ann Surg Oncol 2024 May; 31(5): 3314-3324
    [PubMed ID: 38310181]

  • ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
    Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
    Ann Surg Oncol 2024 Jan; 31(1): 552-553
    [PubMed ID: 37805945]

  • Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy.
    Florissi I, Radomski SN, Shou B, Cloyd JM, Kim A, Grotz T, Fournier K, Baumgartner JM, Lambert L, Abbott DE, Schwartz P, Staley CA, Clarke C, Dineen S, Patel SH, Wilson GC, Raoof M, Johnston FM, Greer JB
    J Surg Res 2024 Jan; 293: 403-412
    [PubMed ID: 37806228]

  • Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
    Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
    Ann Surg Oncol 2024 Jan; 31(1): 488-498
    [PubMed ID: 37782415]

All Publications on PubMed